title: Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.
abstract: C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab.
authors.affiliation: Department of Medicine, Division of Nephrology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Inman
authors.affiliation: Department of Medicine, Division of Nephrology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Ginnie
authors.initials: G
authors.lastname: Prater
authors.affiliation: Department of Pathology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Huma
authors.initials: H
authors.lastname: Fatima
authors.affiliation: Department of Medicine, Division of Nephrology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Wallace
keywords: C3 glomerulopathy; alternative pathway; complement; eculizumab; end-stage renal disease